Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 135Neoplasms 37Pancreatic Neoplasms 34Stomach Neoplasms 27Colonic Neoplasms 23Neoplasm Metastasis 20Rectal Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Esophageal Neoplasms 10Cholangiocarcinoma 10Adenocarcinoma 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Biliary Tract Neoplasms 8Adenocarcinoma Of Esophagus 8Ovarian Neoplasms 7Triple Negative Breast Neoplasms 6Gallbladder Neoplasms 6Esophageal Squamous Cell Carcinoma 6Gastrointestinal Neoplasms 5Digestive System Neoplasms 5Breast Neoplasms 5Advanced Solid Tumors 5Squamous Cell Carcinoma of Head and Neck 4Solid Tumors 4Melanoma 4Intestinal Neoplasms 4Carcinoma, Pancreatic Ductal 4Carcinoma, Hepatocellular 4Advanced Solid Tumor 4Small Cell Lung Carcinoma 3

Interventions

pembrolizumab 3napabucasin 3Bevacizumab 3entinostat 2Paclitaxel 2Ocoxin 2Leucovorin 2Irinotecan 2Immunotherapy 2Gemcitabine 2Fluorouracil 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vorasidenib 1sipuleucel-T 1pralsetinib 1palbociclib 1luprolide acetate gel depot 1linifanib 1lenvatinib 1interferon gamma-1b 1ficlatuzumab 1durvalumab 1catumaxomab 1Vaccines 1VB6-845 fusion protein 1Taxes 1Sorafenib 1Pemetrexed 1Papillomavirus Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms, Glandular and Epithelial × Leucovorin × Clear all
NCT02753127 2023-11-15

CanStem303C

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,253 enrolled 18 charts
Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Colorectal Neoplasms

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡